BeOne Medicines (ONC) Income from Non-Controlling Interests (2017 - 2020)
BeOne Medicines (ONC) reported Income from Non-Controlling Interests of $96000.0 for Q4 2020, down 42.17% year-over-year from $166000.0 in Q1 2020, and up 106.89% on a QoQ basis from -$1.4 million in Q3 2020.
BeOne Medicines (ONC) has 4 years of Income from Non-Controlling Interests data on file, last reported at $96000.0 in Q4 2020.
- Quarterly Income from Non-Controlling Interests fell 42.17% year-over-year to $96000.0 in Q4 2020, while the trailing twelve-month figure through Sep 2021 was $96000.0 (up 102.71% YoY) and the FY2020 annual result came in at -$3.6 million, down 85.49% from the prior year.
- Income from Non-Controlling Interests rose to $96000.0 in Q4 2020 per ONC's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $1.5 million in Q4 2018 and bottomed at -$1.4 million in Q3 2020.
- The 4-year median for Income from Non-Controlling Interests is -$429000.0 (2019), against an average of -$401666.7.
- Peak annual rise in Income from Non-Controlling Interests reached 3493.02% in 2018, while the deepest fall reached 513.33% in 2018.
- Tracing ONC's Income from Non-Controlling Interests over 4 years: stood at $43000.0 in 2017, then soared by 3493.02% to $1.5 million in 2018, then plunged by 89.26% to $166000.0 in 2019, then tumbled by 42.17% to $96000.0 in 2020.
- Per Business Quant, the three latest ONC Income from Non-Controlling Interests figures stand at $96000.0 (Q4 2020), -$1.4 million (Q3 2020), and -$1.1 million (Q2 2020).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | BeOne Medicines | - | - | 1.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 96,000.00 |
| Sep 30, 2020 | -1.39 Mn |
| Jun 30, 2020 | -1.12 Mn |
| Mar 31, 2020 | -1.20 Mn |
| Dec 31, 2019 | 166,000.00 |
| Sep 30, 2019 | -1.30 Mn |
| Jun 30, 2019 | -384,000.00 |
| Mar 31, 2019 | -429,000.00 |
| Dec 31, 2018 | 1.55 Mn |
| Sep 30, 2018 | -461,000.00 |
| Jun 30, 2018 | -828,000.00 |
| Mar 31, 2018 | -520,000.00 |
| Dec 31, 2017 | 43,000.00 |
| Sep 30, 2017 | -102,000.00 |
| Jun 30, 2017 | -135,000.00 |